Zevra Therapeutics
Commercializes U.S.-approved therapies for Niemann-Pick type C disease and certain urea-cycle disorders.
$11.57
After-hours close+0.00 (+0.04%)
At close$11.56(−2.45%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 76.16%45.02M sharesInsiders 1.32%779.8K sharesOther 22.52%13.32M shares
Shares outstanding 59.12M · Float 54.93M · 92.9% free float
Institutions13F, as of Jun 30, 2026
167 holders · 45.02M shares · 31 new positions · 97 increased · 38 reduced · 21 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.11M | 8.64% | +652.4K | Aug 7, 2026 |
| FMR LLC | 4.92M | 8.32% | +1.70M | Aug 13, 2026 |
| Woodline Partners LP | 4.79M | 8.10% | +1.33M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.64M | 4.46% | +169.6K | Aug 13, 2026 |
| Nantahala Capital Management, LLC | 1.80M | 3.04% | −724.5K | Aug 19, 2026 |
| State Street Corp | 1.68M | 2.85% | +120.4K | Aug 7, 2026 |
| Geode Capital Management, LLC | 1.54M | 2.61% | +169.1K | Aug 12, 2026 |
| D. E. Shaw & Co., Inc. | 1.31M | 2.21% | +460.5K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.60% | 4.08M | 13G | Feb 5, 2025 ↗ |
| Woodline Partners LP | 6.20% | 3.48M | 13G | Nov 14, 2025 ↗ |
| FMR LLC | 5.50% | 3.21M | 13G | May 6, 2026 ↗ |
| Vanguard Capital Management | 5.11% | 3.02M | 13G | Jul 31, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Neil F. McFarlane | director, officer: President and CEO | 387.2K | 0.66% | Feb 10, 2026 |
| R. LaDuane Clifton | other: Former CFO & Treasurer | 143.5K | 0.24% | Jan 7, 2026 |
| John B. Bode | director | 84.2K | 0.14% | Mar 26, 2026 |
| Joshua Schafer | officer: CCO | 62.3K | 0.11% | Feb 4, 2026 |
| Rahsaan Thompson | officer: Chief Legal & Compliance | 37.6K | 0.06% | Aug 17, 2026 |
| Timothy J. Sangiovanni | officer: SVP, Finance & Corp Controller | 29.6K | 0.05% | Feb 4, 2026 |
| Alvin Shih | director | 20.0K | 0.03% | Sep 15, 2025 |
| Adrian W. Quartel | officer: Chief Medical Officer | 9.7K | 0.02% | Feb 2, 2026 |
| Tamara A. Favorito | director | 3.9K | 0.01% | Sep 16, 2025 |
| Corey Michael Watton | director | 1.8K | 0.00% | Aug 12, 2026 |
1 person has not refiled in the last 18 months (20.0K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Rahsaan Thompsonofficer: Chief Legal & Compliance | Sale | 42,666 | $11.13 | 37,569 |
| Aug 10, 2026 | Corey Michael Wattondirector | Sale | 12,300 | $11.25 | 1,800 |
| Jun 22, 2026 | Rahsaan Thompsonofficer: Chief Legal & Compliance | Sale | 34,557 | $12.68 | 80,235 |
| May 11, 2026 | Rahsaan Thompsonofficer: Chief Legal & Compliance | Sale | 1,794 | $11.30 | 48,125 |
| Feb 9, 2026 | Neil F. McFarlanedirector, officer: President and CEO | Sale | 14,625 | $8.56 | 387,225 |
| Feb 3, 2026 | Joshua Schaferofficer: CCO | Sale | 10,500 | $9.19 | 62,278 |
| Feb 3, 2026 | Timothy J. Sangiovanniofficer: SVP, Finance & Corp Controller | Sale | 3,000 | $9.18 | 29,590 |
| Feb 2, 2026 | Neil F. McFarlanedirector, officer: President and CEO | Sale | 91,000 | $9.38 | 364,350 |
| Jan 30, 2026 | Joshua Schaferofficer: CCO | Sale | 3,375 | $8.83 | 37,444 |
| Jan 30, 2026 | Adrian W. Quartelofficer: Chief Medical Officer | Sale | 4,533 | $8.83 | 9,723 |
CongressHouse and Senate disclosures
Not reported.